
## PDZ-RhoGEF Antibody

	intibody				
Rabbit Polyclonal		vetein ID			
Antigen Affinity Purified Catalog No. A301–952A		rotein ID	NP_055599.1		
5	-	ienelD	9826	BETHYL	
Lot No. A301-952A-1					
APPLICATIONS	WB, IP, IHC				
SPECIES REACTIVITY	Human				
AMOUNT	100 µl				
CONCENTRATION	200 µg/ml				
STORAGE/SHELF LIFE	2 - 8° C / 1 year fr	2 - 8° C / 1 year from date of receipt			
PHYSICAL STATE	Liquid				
BUFFER	Tris-buffered Salir	Tris-buffered Saline containing 0.1% BSA and 0.09% Sodium Azide			
ISOTYPE	IgG	IgG			
ORIGIN	USA	USA			
PRODUCTION PROCEDURES	Antibody was affir support.	Antibody was affinity purified using an epitope specific to PDZ-RhoGEF immobilized on solid support.			
	The epitope recognized by A301–952A maps to a region between residue 1472 and 1522 of human PDZ-RhoGEF using the numbering given in entry NP_055599.1 (GeneID 9826).				
Immunoglobulin concentration was determined by extinction coefficient: al of 1.4 equals 1.0 mg of IgG.				efficient: absorbance at 280 nm	
APPLICATIONS Centrifuge tube to remove product from lid. Optimal working dilutions should be a experimentally by the investigator. Prepare working dilution immediately before us					
	Western Blot	1:2	,000 - 1:10,000		
	Immunoprecipitat	tion 2 –	5 µg/mg lysate		
	Immunohistocher		00 – 1:500. Epitope retrieval with o ommended for FFPE tissue sections		
APPLICATION NOTES	Western blot of immunoprecipitates performed using Normal Pig Serum (Cat. No. S100–020), Goat anti-Rabbit Light Chain HRP Conjugate (Cat. No. A120–113P) and 4–8% SDS-PAGE (link to IP-western blot protocol in Additional Info section below).				
IHC HUMAN CONTROL	Western blot of lysates performed using standard western blot reagents and 4–8% SDS–PAGE. Breast Carcinoma, Prostate Carcinoma				
ADDITIONAL INFO	https://www.bethyl.com/product/A301-952A Use the link above to view SDS, a current list of citations, and other product specific information. IP-western blot protocol: https://www.bethyl.com/content/protocol_IP_WB				


This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc. Eric McIntush, PhD | Chief Scientific Officer Date: June 21, 2019

Bethyl Laboratories, Inc. • 25043 West FM 1097 • Montgomery, TX 77356 • 800.338.9579 • 936.597.6111 • 866.597.6105 (FAX) • www.bethyl.com • technical@bethyl.com

For in vitro laboratory use only. Not for any clinical, therapeutic or diagnostic use in humans or animals. Not for human or animal consumption. This product may not be resold or modified for resale without the prior written approval of Bethyl Laboratories, Inc. The information provided in this data sheet is believed to be correct but does not purport to be all-inclusive and is intended to be used as a guide. Bethyl Laboratories, Inc. shall not be liable or responsible in any way for use of either this information or the material supplied. Disposal of hazardous material may be subject to federal, state or local laws or regulations.



Detection of human PDZ-RhoGEF by western blot and immunoprecipitation. *Samples:* Whole cell lysate (5, 15 and 50 µg for WB; 1 mg for IP, 20% of IP loaded) from HeLa cells. *Antibodies:* Affinity purified rabbit anti-PDZ-RhoGEF antibody A301-952A used for WB at 0.04 µg/ml (A) and 1 µg/ml (B) and used for IP at 3 µg/mg lysate. PDZ-RhoGEF was also immunoprecipitated by rabbit anti-PDZ-RhoGEF antibody A301-951A, which recognizes an upstream epitope. *Detection:* Chemiluminescence with exposure times of 30 seconds (A) and 10 seconds (B).



Detection of human PDZ-RhoGEF by

**immunohistochemistry.** *Sample:* FFPE section of human prostate carcinoma. *Antibody:* Affinity purified rabbit anti-PDZ-RhoGEF (Cat. No. A301-952A Lot1) used at a dilution of 1:200 (1µg/ml). *Detection:* DAB